Background:Approximately 10%–30%of patients with Hodgkin’s lymphoma(HL)experience relapse or refractory(R/R)disease after first-line standard therapy.Brentuximab vedotin(BV)and immune checkpoint inhibitors(ICIs)have...Background:Approximately 10%–30%of patients with Hodgkin’s lymphoma(HL)experience relapse or refractory(R/R)disease after first-line standard therapy.Brentuximab vedotin(BV)and immune checkpoint inhibitors(ICIs)have important roles in the salvage treatment of R/R HL.However,subsequent treatment for HL refractory to BV and/or ICI treatment is challenging.Methods:We retrospectively analyzed patients in two institutions who had R/R HL,experienced BV or ICI treatment failure,and received radiotherapy(RT)thereafter.The overall response rate(ORR),duration of response(DOR),progression-free survival(PFS),and overall survival(OS)were analyzed.Results:Overall,19 patients were enrolled.First-line systemic therapy comprised doxorubicin,bleomycin,vinblastine,and dacarbazine(ABVD,84.2%);AVD plus ICIs(10.5%);and bleomycin,etoposide,doxorubicin,cyclophosphamide,vincristine,procarbazine,and prednisone(BEACOPP,5.3%).After first-line therapy,15(78.9%)and four patients(21.1%)had refractory disease and relapsed,respectively.After R/R HL diagnosis,six(31.6%),two(10.5%),and 11(57.9%)patients received BV and ICIs concurrently,BV monotherapy,and ICI monotherapy,respectively.All patients received intensity-modulated RT(n=12,63.2%)or volumetric modulated arc therapy(VMAT;n=7,36.8%).The ORR as well as the complete response(CR)rate was 100%;the median DOR to RT was 17.2 months(range,7.9–46.7 months).Two patients showed progression outside the radiation field;one patient had extensive in-field,out-of-field,nodal,and extranodal relapse.With a median follow-up time of 16.2 months(range,9.2–23.2 months),the 1-year PFS and OS were 84.4%and 100%,respectively.PFS was associated with extranodal involvement(P=0.019)and gross tumor volume(P=0.044).All patients tolerated RT well without adverse events of grade≥3.Conclusion:RT is effective and safe for treating HL refractory to BV or ICIs and has the potential to be part of a comprehensive strategy for HL.展开更多
Objective Bufalin,the main active anti-tumor monomer of toad venom,is crucial in cancer treatment.However,intrinsic issues,such as poor solubility and systematic toxicity,have considerably mitigated its anticancer fun...Objective Bufalin,the main active anti-tumor monomer of toad venom,is crucial in cancer treatment.However,intrinsic issues,such as poor solubility and systematic toxicity,have considerably mitigated its anticancer functions and caused unwanted side effects.It is essential to develop innovative targeting systems to precisely and efficiently deliver anticancer drugs to achieve satisfying therapeutic efficiency.Methods This work established a novel and more efficient system for simultaneously detecting and killing colorectal cancer cells.The proposed method designed two allosteric probes,a report probe and a recognize probe.The method exhibited high sensitivity towards cell detection via the recognizing probe identifying target cancer cells and the report probe’s signal report.Combining bufalin and fluorouracil endowed better tumor cell inhibition.Results We observed significantly enhanced fluorescence dots surrounding the HCT-116 cell membranes.No fluorescence increments in the other three cells were identified,indicating that the established liposome complex could specifically bind with target cells.In addition,the best ratio of bufalin to fluorouracil was 0.15 and 0.5,respectively.This improved the anti-tumor effects and achieved more than 60%tumor cell inhibition.Conclusion This method will provide new opportunities for intracellular biomolecule detection and targeted cancer cell therapy.展开更多
基金supported by grants from the Major Scientific Research Program for Young and Middle-aged Health Professionals of Fujian Province,China(grant number:2022ZQNZD002)the Fujian Key Laboratory of Intelligent Imaging and Precision Radiotherapy for Tumors(Fujian Medical University)and Clinical Research Center for Radiology and Radiotherapy of Fujian Province(Digestive,Hematological and Breast Malignancies).
文摘Background:Approximately 10%–30%of patients with Hodgkin’s lymphoma(HL)experience relapse or refractory(R/R)disease after first-line standard therapy.Brentuximab vedotin(BV)and immune checkpoint inhibitors(ICIs)have important roles in the salvage treatment of R/R HL.However,subsequent treatment for HL refractory to BV and/or ICI treatment is challenging.Methods:We retrospectively analyzed patients in two institutions who had R/R HL,experienced BV or ICI treatment failure,and received radiotherapy(RT)thereafter.The overall response rate(ORR),duration of response(DOR),progression-free survival(PFS),and overall survival(OS)were analyzed.Results:Overall,19 patients were enrolled.First-line systemic therapy comprised doxorubicin,bleomycin,vinblastine,and dacarbazine(ABVD,84.2%);AVD plus ICIs(10.5%);and bleomycin,etoposide,doxorubicin,cyclophosphamide,vincristine,procarbazine,and prednisone(BEACOPP,5.3%).After first-line therapy,15(78.9%)and four patients(21.1%)had refractory disease and relapsed,respectively.After R/R HL diagnosis,six(31.6%),two(10.5%),and 11(57.9%)patients received BV and ICIs concurrently,BV monotherapy,and ICI monotherapy,respectively.All patients received intensity-modulated RT(n=12,63.2%)or volumetric modulated arc therapy(VMAT;n=7,36.8%).The ORR as well as the complete response(CR)rate was 100%;the median DOR to RT was 17.2 months(range,7.9–46.7 months).Two patients showed progression outside the radiation field;one patient had extensive in-field,out-of-field,nodal,and extranodal relapse.With a median follow-up time of 16.2 months(range,9.2–23.2 months),the 1-year PFS and OS were 84.4%and 100%,respectively.PFS was associated with extranodal involvement(P=0.019)and gross tumor volume(P=0.044).All patients tolerated RT well without adverse events of grade≥3.Conclusion:RT is effective and safe for treating HL refractory to BV or ICIs and has the potential to be part of a comprehensive strategy for HL.
基金Supported by grants from the Medical Guidance Project of Shanghai Science and Technology Commission(No.19401935200)the Budget Internal Medicine Research Project of Shanghai University of Traditional Chinese Medicine(No.2020LK065).
文摘Objective Bufalin,the main active anti-tumor monomer of toad venom,is crucial in cancer treatment.However,intrinsic issues,such as poor solubility and systematic toxicity,have considerably mitigated its anticancer functions and caused unwanted side effects.It is essential to develop innovative targeting systems to precisely and efficiently deliver anticancer drugs to achieve satisfying therapeutic efficiency.Methods This work established a novel and more efficient system for simultaneously detecting and killing colorectal cancer cells.The proposed method designed two allosteric probes,a report probe and a recognize probe.The method exhibited high sensitivity towards cell detection via the recognizing probe identifying target cancer cells and the report probe’s signal report.Combining bufalin and fluorouracil endowed better tumor cell inhibition.Results We observed significantly enhanced fluorescence dots surrounding the HCT-116 cell membranes.No fluorescence increments in the other three cells were identified,indicating that the established liposome complex could specifically bind with target cells.In addition,the best ratio of bufalin to fluorouracil was 0.15 and 0.5,respectively.This improved the anti-tumor effects and achieved more than 60%tumor cell inhibition.Conclusion This method will provide new opportunities for intracellular biomolecule detection and targeted cancer cell therapy.
